{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T06:12:09Z","timestamp":1675145529043},"reference-count":27,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.vaccine.2006.02.048","type":"journal-article","created":{"date-parts":[[2006,3,14]],"date-time":"2006-03-14T13:48:09Z","timestamp":1142344089000},"page":"4409-4416","source":"Crossref","is-referenced-by-count":2,"title":["Recombinant hepatitis B large surface antigen, successfully produced in Escherichia coli, stimulates T-cell response in mice"],"prefix":"10.1016","volume":"24","author":[{"given":"Li","family":"Shu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Touzjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deng","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amie J.","family":"Strong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zeping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geng","family":"Zhaohui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.02.048_bib1","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0140-6736(05)65598-5","article-title":"Global status of hepatitis B immunization","volume":"348","author":"Kane","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2006.02.048_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7150\/ijms.2.24","article-title":"Advances in immunomodulating therapy of HBV infection","volume":"2","author":"Hui","year":"2005","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.vaccine.2006.02.048_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0002-9440(10)64980-2","article-title":"Rous\u2013Whipple award lecture. Viruses, immunity, and cancer: lessons from hepatitis B","volume":"156","author":"Chisari","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vaccine.2006.02.048_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","article-title":"Noncytolytic control of viral infections by the innate and adaptive immune response","volume":"19","author":"Guidotti","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2006.02.048_bib5","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1073\/pnas.91.9.3764","article-title":"Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice","volume":"91","author":"Guidotti","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2006.02.048_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2006.02.048_bib7","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/JVI.71.4.3236-3243.1997","article-title":"Interleukin-12 inhibits hepatitis B virus replication in transgenic mice","volume":"71","author":"Cavanaugh","year":"1997","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.02.048_bib8","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1128\/JVI.72.4.2630-2637.1998","article-title":"Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infection in transgenic mice","volume":"72","author":"Cavanaugh","year":"1998","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.02.048_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1084\/jem.192.2.289","article-title":"Inhibition of hepatitis B virus replication during Schistosoma mansoni infection in transgenic mice","volume":"192","author":"McClary","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2006.02.048_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/viro.2000.0442","article-title":"Cytokine-mediated control of viral infections","volume":"273","author":"Guidotti","year":"2000","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.vaccine.2006.02.048_bib11","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1128\/JVI.76.6.2617-2621.2002","article-title":"Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice","volume":"76","author":"Guidotti","year":"2002","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2006.02.048_bib12","doi-asserted-by":"crossref","first-page":"10702","DOI":"10.1128\/JVI.76.21.10702-10707.2002","article-title":"Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice","volume":"76","author":"Kimura","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.02.048_bib13","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.vaccine.2006.02.048_bib14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.02.048_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJM199504203321604","article-title":"Association between an MHC class II allele and clearance of hepatitis B virus in The Gambia","volume":"332","author":"Thursz","year":"1995","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.vaccine.2006.02.048_bib16","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.1128\/JVI.77.22.12083-12087.2003","article-title":"Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection","volume":"77","author":"Thio","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.02.048_bib17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.181.3.1047","article-title":"The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis","volume":"181","author":"Rehermann","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2006.02.048_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.iy.13.040195.000333","article-title":"Hepatitis B virus immunopathogenesis","volume":"13","author":"Chisari","year":"1995","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2006.02.048_bib19","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1172\/JCI119308","article-title":"Cytotoxic T cell and viral hepatitis","volume":"99","author":"Chisari","year":"1997","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.vaccine.2006.02.048_bib20","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1172\/JCI118592","article-title":"Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection","volume":"97","author":"Rehermann","year":"1996","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1016\/j.vaccine.2006.02.048_bib21","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1073\/pnas.97.14.8027","article-title":"Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity","volume":"97","author":"Lu","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.vaccine.2006.02.048_bib22","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1073\/pnas.1131930100","article-title":"A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen","volume":"100","author":"Kushner","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2006.02.048_bib23","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1016\/j.vaccine.2005.03.022","article-title":"Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways","volume":"23","author":"McEvers","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2006.02.048_bib24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1086\/338448","article-title":"Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol","volume":"185","author":"Cao","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2006.02.048_bib25","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/JVI.68.3.1418-1425.1994","article-title":"Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis","volume":"68","author":"Schirmbeck","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2006.02.048_bib26","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.4049\/jimmunol.168.10.4951","article-title":"Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain","volume":"168","author":"Riedl","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.02.048_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0960-9822(02)00482-7","article-title":"Codon usage limitation in the expression of HIV-1 envelope glycoprotein","volume":"6","author":"Haas","year":"1996","journal-title":"Curr Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06002337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06002337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T04:53:14Z","timestamp":1586753594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06002337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":27,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0264410X06002337"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.02.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}